Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated ...

Explore the advantages and challenges of long-term red blood cell transfusions for low-risk MDS patients, focusing on quality ...

Exploring the impact of inflammation in MDS, this article highlights the need for novel therapies to enhance patient quality ...

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, ...

A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment ...

A recent post‑hoc analysis of the COMMANDS trial evaluated the benefits of Luspatercept versus Epoetin alfa (EA) in ESA‑naïve ...

A recent study explores inflammatory profiles in low-risk MDS, revealing distinct patient categories and implications for ...

A recent study highlights the benefits of early luspatercept treatment for patients with hemoglobin above 8, improving ...

A recent study highlights the effectiveness of Luspatercept in first-line treatment, showing significant patient benefits and ...

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks ...